Immunome, Inc. · NASDAQ:IMNM
Immunome — Investor Presentation (July 2021)
30 slides from Immunome's investor presentation, Jul 20, 2021
Slide 1: Harnessing the Human Memory B Cell Response To Develop Antibody-Based Therapeutics
Copyright © 2021 Immunome, Inc. All rights reserved. Harnessing the Human Memory B Cell Response To Develop Antibody - Based Therapeutics July 20, 2021 Immunome, Inc. 665 Stockton Drive, Suite 300 | Exton, PA 19341 610.321.3700 | www.immunome.com
Slide 2: Forward Looking Statements
2 Copyright © 2021 Immunome, Inc. All rights reserved. Forward Looking Statements This presentation includes certain disclosures that contain “forward - looking statements” intended to qualify for the “safe harbor” from liability established by the Private Securities Litigation Reform Act of 1995, a
Slide 3: Management Team
Copyright © 2021 Immunome, Inc. All rights reserved. 3 Management Team Michael Morin, PhD Chief Scientific Officer Dennis Giesing , PhD Chief Development Officer Purnanand Sarma, PhD President & CEO Sandra Stoneman, Esq. Chief Legal Officer Corleen Roche Chief Financial Officer Matthew Robinson, PhD
Slide 4: Immunome Highlights
Copyright © 2021 Immunome, Inc. All rights reserved. 4 Immunome Highlights Discovery Engine • Rapid, unbiased interrogation of memory B cells to identify novel targets and antibodies directed at them • Plan to advance one or more product candidates into development by end of 2021 • Multiple opportun
Slide 5: Immunome Development Pipeline and Anticipated Key Milestones
5 Copyright © 2021 Immunome, Inc. All rights reserved. Immunome Development Pipeline and Anticipated Key Milestones ONCOLOGY TARGET PRODUCT CANDIDATE DESCRIPTION DISCOVERY PRECLINICAL ANTICIPATED NEXT MILESTONE IMM - BCP - 01 Three SARS - CoV - 2 Epitopes Three antibody cocktail IND filing Q3 2021 A
Slide 6: The Power of Memory B Cells
Copyright © 2021 Immunome, Inc. All rights reserved. 6 The Power of Memory B Cells Immunome’s Discovery Engine Sees Disease Through the Lens of the Human Memory B Cell • Memory B cells remember specific antigens and allow for a rapid antibody response 1 • The antibodies that these cells produce are
Slide 7: Discovery Engine: Unbiased Interrogation of Memory B Cells
Copyright © 2021 Immunome, Inc. All rights reserved. 7 Discovery Engine Unbiased Interrogation of Memory B Cells Antibody Screening Deep, multiplexed interrogation of patient memory B cell responses Patient Response Capture memory B cells from cancer or infectious disease patients Antibody Validatio
Slide 8: Infectious Disease
Copyright © 2021 Immunome, Inc. All rights reserved. 8 Infectious Disease
Slide 9: IMM-BCP-01 Antibody Cocktail Against Three SARS-CoV-2 Epitopes
Copyright © 2021 Immunome, Inc. All rights reserved. 9 IMM - BCP - 01 Antibody Cocktail Against Three SARS - CoV - 2 Epitopes Collaboration with U.S. DoD awarded up to $17.6M in funding Select convalescent patients with strong anti - viral titer Antibody cocktail for potential prophylaxis and treatm
Slide 10: Evolving SARS-CoV-2 Landscape: IMM-BCP-01 Designed to Meet the Threat
Copyright © 2021 Immunome, Inc. All rights reserved. 10 SARS - CoV - 2 Evolving Landscape IMM - BCP - 01 Designed to Meet The Threat Of Emerging SARS - CoV - 2 Variants SARS - CoV - 2 Continues To Mutate Resulting in New Escape Mutants • Certain variants exhibit increased transmission and decrease t
Slide 11: IMM-BCP-01 Triangulating the Spike Protein: Three Non-Overlapping Regions
Copyright © 2021 Immunome, Inc. All rights reserved. 11 IMM - BCP - 01 Triangulating the Spike Protein: Targeting Three Non - Overlapping Regions x Antibody A : binds to ACE2 binding site, highly potent neutralizer x Antibody B : binds to an epitope conserved in all CoV - 2 variants tested to date x
Slide 12: IMM-BCP-01 Antibody Cocktail Efficacy Across Multiple Variants in Pre-clinical Testing
Copyright © 2021 Immunome, Inc. All rights reserved. 12 IMM - BCP - 01 Antibody Cocktail Approach Translates to Efficacy Across Multiple Variants in Pre - clinical Testing • Pseudovirus neutralization across multiple strains • CDC SARS - CoV - 2 Variants of Concern (07/19/21) • Live virus neutraliza
Slide 13: IMM-BCP-01 Neutralizes CDC Variants of Concern in Pseudovirus Testing
Copyright © 2021 Immunome, Inc. All rights reserved. 13 IMM - BCP - 01 Neutralizes CDC Variants of Concern in Pseudovirus Testing • Alpha, Beta, Gamma and Delta » CDC Variants of Concern (as of 07/19/2021) • US and European reference strains, USA - WA1/2020 and BavPat1/2020 • Activity maintained ove
Slide 14: IMM-BCP-01 Robust Activity in In-Vitro Live Virus and Infected Hamster Models
Copyright © 2021 Immunome, Inc. All rights reserved. 14 IMM - BCP - 01 Exhibits Robust Activity in In - Vitro Live Virus and Infected Hamster Models – Select Examples Antibody Cocktail Neutralizes UK (B.1.1.7) Antibody Cocktail Reduces Viral Lung Titer • IMM - BCP - 01 live virus neutralization in v
Slide 15: IMM-BCP-01 Antibody Cocktail With Potent Pre-clinical Activity Against Variants
Copyright © 2021 Immunome, Inc. All rights reserved. 15 IMM - BCP - 01 Antibody Cocktail With Potent Pre - clinical Activity Against SARS - CoV - 2 Variants of Concern x Binding to three non - overlapping regions of receptor binding domain (RBD), leading to combinatorial activity x Neutralize multip
Slide 16: Oncology
Copyright © 2021 Immunome, Inc. All rights reserved. 16 Oncology
Slide 17: Immunome's Discovery & Output: Target Rich Functional Clusters
Copyright © 2021 Immunome, Inc. All rights reserved. 17 Immunome’s Discovery & Output Memory B Cells Interrogation Reveals Target Rich Functional “Clusters” • Common biological processes that may have disease relevance, such as exosome control of the tumor microenvironment 1 - 2 • Novel immune check
Slide 18: B Cell Immunity Offers Access to Multiple Antitumor Mechanisms
Copyright © 2021 Immunome, Inc. All rights reserved. 18 The Power of Memory B Cells B Cell Immunity Offers Access to Multiple Antitumor Mechanisms Tumor - derived Factors/ metastatic cells Target - specific antibodies Tumor of B Cell Donor Responding Patient Immune Modulation Exosomes & Membrane Dyn
Slide 19: Oncology R&D Pipeline
Copyright © 2021 Immunome, Inc. All rights reserved. 19 Oncology R&D Pipeline Mapping the Tumor Through the Lens of the B Cell Identifies Unique Therapeutic Targets Immune Modulators Exosomes & Membrane Dynamics Tumor or Tumor - Associated Stromal Antigens Program Pathways Potential Cancers of Relev
Slide 20: IL-38: A Novel Oncology Target
Copyright © 2021 Immunome, Inc. All rights reserved. 20 IL - 38: A Novel Oncology Target IL - 38 Appears to Dampen Innate Anti - Tumor Immunity • IL - 38 is an IL - 1 cytokine family member, but most closely resembles the natural antagonists of the family (IL - 1Ra and IL - 36a) • IL - 38 inhibits i
Slide 21: IL-38 Expression in Solid Tumors
Copyright © 2021 Immunome, Inc. All rights reserved. 21 IL - 38 Expression in Solid Tumors IL - 38 is Over - Expressed in Multiple Tumors of High Unmet Medical Need, and Associated with Reduced Immune Cell Infiltration IL - 38 is over - expressed in multiple tumors of high unmet medical need Inverse
Slide 22: Clinical Consequences of IL-38 Expression
Copyright © 2021 Immunome, Inc. All rights reserved. 22 Clinical Consequences of IL - 38 Expression Recent Literature Reports Show Correlation Between IL - 38 and Tumor Growth IL - 38 high IL - 38 low
Slide 23: IMM-ONC-01 Blocking IL-38 Leads to Tumor Control in Two Tumor Models
Copyright © 2021 Immunome, Inc. All rights reserved. 23 IMM - ONC - 01 Blocking IL - 38 Leads to Tumor Control in Two Different Tumor Models Demonstration of Anti - Tumor Activity (B16F10 Model) Induction of Anti - Tumor Memory (EMT6 Model) • Immunologically cold tumor model • IMM - ONC - 01 equival
Slide 24: IMM-ONC-01 Program Summary
Copyright © 2021 Immunome, Inc. All rights reserved. 24 IMM - ONC - 01 Program Summary Modulating Innate Anti - Tumor Immunity • IL - 38 is a novel checkpoint in the innate immune system » Target of an antibody isolated from the memory B cells of a patient with head and neck cancer • Targeting IL -
Slide 25: Summary
Copyright © 2021 Immunome, Inc. All rights reserved. 25 Summary •
Slide 26: Intellectual Property and Finance
Copyright © 2021 Immunome, Inc. All rights reserved. 26 Broad patent estate covering technology and applications Exclusively licensed patents from key academic institutions Significant additional intellectual property generated by Immunome Intellectual Property and Finance Traded on NASDAQ under Tic
Slide 27: Immunome Summary
Copyright © 2021 Immunome, Inc. All rights reserved. 27 Immunome Summary Discovery Engine • Rapid, unbiased interrogation of memory B cells to identify novel targets and antibodies directed at them • Plan to advance one or more product candidates into development by end of 2021 • Multiple opportunit
Slide 28: Appendix
Copyright © 2021 Immunome, Inc. All rights reserved. 28 Appendix
Slide 29: Scientific Advisory Board
Copyright © 2021 Immunome, Inc. All rights reserved. 29 Scientific Advisory Board Scott Dessain, MD, PhD Chair, Founder Joseph and Ray Gordon Chair of Clinical Oncology and Research at Lankenau Institute for Medical Research George Prendergast, PhD Cancer Biology Former Editor of Cancer Research Pre
Slide 30: Board of Directors
Copyright © 2021 Immunome, Inc. All rights reserved. 30 Board of Directors Mike Rapp, Chairman Managing Partner, Broadband Capital Investments, LLC Richard Baron Formerly Chief Financial Officer, Zynerba Pharmaceuticals John LaMattina, PhD Formerly President, Pfizer Global Research & Development Mic